Microbiological and Pathological Findings
. | Control . | rhG-CSF . | rhIL-11 . | rhG-CSF + rhIL-11 . |
---|---|---|---|---|
% Bacteremia (95%-CI) | 82% (74% to 90%) | 100% (80% to 100%) | 88% (81% to 96%) | 75% (68% to 82%) |
CFU/mL-blood | 184 ± 99 | 146 ± 101 | 17 ± 113 | 27 ± 81 |
LPS (pg/mL) | 389 ± 162 | 262 ± 189 | 49 ± 16* | 26 ± 13* |
GI path (0-4) | 4 ± 0.5 | 4 ± 0.5 | 1.1 ± 0.6† | 0.7 ± 0.6* |
CFU/mg—tissue | 474 ± 328 | 99 ± 51 | 2.5 ± 0.9* | 3.3 ± 1.6* |
. | Control . | rhG-CSF . | rhIL-11 . | rhG-CSF + rhIL-11 . |
---|---|---|---|---|
% Bacteremia (95%-CI) | 82% (74% to 90%) | 100% (80% to 100%) | 88% (81% to 96%) | 75% (68% to 82%) |
CFU/mL-blood | 184 ± 99 | 146 ± 101 | 17 ± 113 | 27 ± 81 |
LPS (pg/mL) | 389 ± 162 | 262 ± 189 | 49 ± 16* | 26 ± 13* |
GI path (0-4) | 4 ± 0.5 | 4 ± 0.5 | 1.1 ± 0.6† | 0.7 ± 0.6* |
CFU/mg—tissue | 474 ± 328 | 99 ± 51 | 2.5 ± 0.9* | 3.3 ± 1.6* |